

Ref. No: 2089  
Date: 02/10/25  
Subject: Biologic medicines in gastroenterology

## REQUEST & RESPONSE

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira - 6
- Adalimumab Biosimilar - 154
- Etrasimod - 0
- Filgotinib - 14
- Golimumab - <5
- Infliximab – Remicade - <5
- Infliximab Biosimilar - 285
- Mirikizumab - 17
- Ozanimod - 6
- Risankizumab - 26
- Tofacitinib - 14
- Upadacitinib - 18
- Ustekinumab – Stelara - 12
- Ustekinumab Biosimilar - 164
- Vedolizumab - 116

2. Could you please provide the numbers of patients treated for Crohn's Disease in the last 3 months with the following biologic drugs:

- Adalimumab – Humira <5
- Adalimumab Biosimilars 15
- Golimumab 0
- Infliximab – Remicade 0
- Infliximab Biosimilars 35
- Risankizumab 6
- Upadacitinib <5
- Ustekinumab – Stelara <5
- Ustekinumab Biosimilar 23
- Vedolizumab 15
- Mirikizumab 0

<5

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).